BridgeBio Oncology CEO granted 1,103,837 options

BridgeBio Oncology Therapeutics reported that President and CEO Pedro Beltran received a grant of stock options covering 1,103,837 shares of common stock.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics reported that President and CEO Pedro Beltran received a grant of stock options covering 1,103,837 shares of common stock. The options have an exercise price of $7.66 per share and were awarded at no cost to him.

These options expire on May 9, 2036 and vest in substantially equal monthly installments, with 1/48 of the total vesting on each monthly anniversary of April 20, 2026, contingent on his continued service. Following this grant, he holds options for 1,103,837 shares directly.

Insider Trade Summary

Grant/Award: 1,103,837 shares

Grant/Award 1 txn

Insider Beltran Pedro

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,103,837	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,103,837 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Option grant size: 1,103,837 shares Exercise price: $7.66 per share Post-grant option holdings: 1,103,837 shares +2 more

5 metrics

Option grant size 1,103,837 shares Stock Option (Right to Buy) granted to CEO

Exercise price $7.66 per share Conversion or exercise price of granted options

Post-grant option holdings 1,103,837 shares Total options held following transaction

Option expiration date May 9, 2036 Expiration of CEO stock options

Vesting schedule 1/48 monthly Vests each month from April 20, 2026, subject to service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.6600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to such option vest and become exercisable in substantially equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-05-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BBOT CEO Pedro Beltran receive in this Form 4 filing?

Pedro Beltran received a stock option grant for 1,103,837 shares of BridgeBio Oncology common stock. The options are compensation, not an open-market purchase, and give him the right to buy shares at a fixed exercise price of $7.66 per share.

What is the exercise price of the new BBOT CEO stock options?

The stock options granted to Pedro Beltran have an exercise price of $7.66 per share. This means he can buy BridgeBio Oncology common stock at $7.66 once options vest, regardless of the market price at the time of exercise.

How do the BBOT CEO stock options vest over time?

The options vest in monthly installments, with 1/48 of the shares vesting on each monthly anniversary of April 20, 2026. Vesting is conditional on Pedro Beltran’s continuous service with BridgeBio Oncology on each vesting date.

When do Pedro Beltran’s BridgeBio Oncology options expire?

The granted stock options expire on May 9, 2036. If any options are not exercised by that date, the right to purchase those BridgeBio Oncology common shares at the $7.66 exercise price will lapse and become void.

How many BridgeBio Oncology option shares does the CEO hold after this grant?

After this grant, Pedro Beltran holds options for 1,103,837 shares of BridgeBio Oncology common stock directly. This figure reflects the total stock option position reported for him in this filing following the grant transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beltran Pedro

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.66	05/10/2026		A		1,103,837		(1)	05/09/2036	Common Stock	1,103,837	$0	1,103,837	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)